FK506(Tacrolimus)is a systemic immunosuppressant approved by the U.S.Food and Drug Administration.FK506 has been shown to promote peripheral nerve regeneration,however,its precise mechanism of action and its pathways ...FK506(Tacrolimus)is a systemic immunosuppressant approved by the U.S.Food and Drug Administration.FK506 has been shown to promote peripheral nerve regeneration,however,its precise mechanism of action and its pathways remain unclear.In this study,we established a rat model of sciatic nerve injury and found that FK506 improved the morphology of the injured sciatic nerve,increased the numbers of motor and sensory neurons,reduced inflammatory responses,markedly improved the conduction function of the injured nerve,and promoted motor function recovery.These findings suggest that FK506 promotes peripheral nerve structure recovery and functional regeneration by reducing the intensity of inflammation after neuronal injury and increasing the number of surviving neurons.展开更多
FK506结合蛋白样蛋白(FK506-binding protein like,FKBPL)是亲免素家族的一员,其功能十分广泛,可以调控类固醇受体的信号转导,抑制肿瘤干细胞及肿瘤细胞的生长,并且能够作为肿瘤预后的生物学标志物。最新研究发现,它的N端区域存在抗血...FK506结合蛋白样蛋白(FK506-binding protein like,FKBPL)是亲免素家族的一员,其功能十分广泛,可以调控类固醇受体的信号转导,抑制肿瘤干细胞及肿瘤细胞的生长,并且能够作为肿瘤预后的生物学标志物。最新研究发现,它的N端区域存在抗血管生成结构域,可在体内和体外发挥抗血管生成作用。此外,FKBPL还与炎症、眼部疾病、心理疾病等诸多问题相关。文章主要从FKBPL的结构和功能出发,对FKBPL的功能研究进展进行综述,并探讨其在临床应用中的前景。展开更多
基金supported by the National Natural Science Foundation of China,No.81971177(to YK)the Natural Science Foundation of Beijing,No.7222198(to NH)the Peking University People's Hospital Research and Development Fund,No.RDX2021-01(to YK)。
文摘FK506(Tacrolimus)is a systemic immunosuppressant approved by the U.S.Food and Drug Administration.FK506 has been shown to promote peripheral nerve regeneration,however,its precise mechanism of action and its pathways remain unclear.In this study,we established a rat model of sciatic nerve injury and found that FK506 improved the morphology of the injured sciatic nerve,increased the numbers of motor and sensory neurons,reduced inflammatory responses,markedly improved the conduction function of the injured nerve,and promoted motor function recovery.These findings suggest that FK506 promotes peripheral nerve structure recovery and functional regeneration by reducing the intensity of inflammation after neuronal injury and increasing the number of surviving neurons.
文摘FK506结合蛋白样蛋白(FK506-binding protein like,FKBPL)是亲免素家族的一员,其功能十分广泛,可以调控类固醇受体的信号转导,抑制肿瘤干细胞及肿瘤细胞的生长,并且能够作为肿瘤预后的生物学标志物。最新研究发现,它的N端区域存在抗血管生成结构域,可在体内和体外发挥抗血管生成作用。此外,FKBPL还与炎症、眼部疾病、心理疾病等诸多问题相关。文章主要从FKBPL的结构和功能出发,对FKBPL的功能研究进展进行综述,并探讨其在临床应用中的前景。
文摘目的 研制可植入玻璃体的FK506控释药膜,并评价其在兔玻璃体腔内的释药动力学过程及毒副作用。方法 HPLC/MS/MS法测定FK506控释药膜植入玻璃体后3个月内眼内组织及全血中的FK506浓度,观察该药膜植入兔眼后1个月内的毒性反应。结果FK506控释药膜植入兔玻璃体3个月内,玻璃体的平均药物质量浓度为41.57ng/ml,而全血中仅为0.25ng/ml。裂隙灯显微镜、ERG及组织学检查均显示FK 506控释药膜植入兔眼后1个月内未发生局部毒性反应。结论 可植入性FK506控释药膜植入兔玻璃体后,以较恒定的速率释放FK 506,使眼内组织在较长时间内维持较稳定的 FK 506浓度。兔眼对 FK 506控释药膜表现出良好的耐受性。
